Last updated 2026-07-20
- Acquired by Venus MedTech Inc. for $300M, 2022
Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Rounds' value
—
total disclosed, rounds participated
Stages
—
About
Amir Gross is a serial entrepreneur and executive with a strong track record in the health tech sector. He co-founded and served as CEO of Cardiovalve, which was acquired by Venus MedTech for $300M in 2022. Previously, he founded and served as CEO of Valtech Cardio, which was acquired by Edwards LifeSciences for $700M in 2017. Gross's expertise lies in developing innovative solutions for percutaneous mitral valve technologies. He is also an angel investor in several Israeli startups.
Portfolio
No portfolio companies in this dataset yet.
Investment activity
1 portfolio exit on record.
Portfolio by sector
Fintech & Insurtech1
Health Tech & Life Sciences1
Q&A
- What was Amir Gross's most recent exit?
- Amir Gross exited Cardiovalve in March 2022 when it was acquired by Venus Medtech for $150M.
- Which sectors has Amir Gross focused on for investments?
- Amir Gross has invested in companies across the Fintech & Insurtech and Health Tech & Life Sciences sectors. One notable portfolio company in Health Tech & Life Sciences is Cardiovalve.
- Can you name a recent investment by Amir Gross?
- Amir Gross invested in Tipigo, an AI-driven portfolio management company, in a Seed round in May 2016.
- What is the typical investment stage for Amir Gross?
- Amir Gross has participated in Seed stage investments, such as the one in Tipigo.
- What is the total amount raised by portfolio company Cardiovalve?
- Cardiovalve, a portfolio company of Amir Gross, raised $45.48M before its acquisition.
- What is the business model of Tipigo, a company in Amir Gross's portfolio?
- Tipigo operates on a B2B business model, providing artificial intelligence for portfolio management.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2005 |
|---|
Acquisitions & public offerings
Acquired by Venus MedTech Inc. 2022 $300.0M
Radar intelligence
Patents
| EPO | 26 |
|---|